Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

NCT04708054 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

324

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: Busulfan
DRUG: Cladribine
DRUG: Fludarabine Phosphate
PROCEDURE: Hematopoietic Cell Transplantation
DRUG: Thiotepa
DRUG: Venetoclax

Sponsor

M.D. Anderson Cancer Center